Man Group’s Axsome Therapeutics AXSM Stock Holding History

Man Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.2M	Sell	82,526 -59,745	-42%	-$13M	0.03%	503
2026 Q1	$24M	Sell	142,271 -86,370	-38%	-$14.9M	0.04%	430
2025 Q4	$41.8M	Sell	228,641 -59,267	-21%	-$8.27M	0.07%	279
2025 Q3	$35M	Sell	287,908 -237,161	-45%	-$26.7M	0.06%	338
2025 Q2	$54.8M	Buy	525,069 +11,848	+2%	+$1.25M	0.1%	218
2025 Q1	$59.9M	Buy	513,221 +349,833	+214%	+$39.9M	0.15%	150
2024 Q4	$13.8M	Buy	+163,388	New	+$15M	0.04%	597
2023 Q1	–	Sell	-116,492	Closed	-$8.99M	–	2075
2022 Q4	$8.99M	Buy	+116,492	New	+$6.96M	0.03%	616
2021 Q3	–	Sell	-7,994	Closed	-$539K	–	1896
2021 Q2	$539K	Sell	7,994 -33,907	-81%	-$2.03M	﹤0.01%	1540
2021 Q1	$2.37M	Buy	41,901 +1,395	+3%	+$98.1K	0.01%	1039
2020 Q4	$3.3M	Sell	40,506 -2,304	-5%	-$172K	0.01%	998
2020 Q3	$3.05M	Buy	42,810 +28,383	+197%	+$2.21M	0.01%	1041
2020 Q2	$1.19M	Buy	+14,427	New	+$1.11M	0.01%	1225

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Man Group's AXSM Position: Q2 2026 in Review

Man Group reduced its Axsome Therapeutics (AXSM) stake by 42% in Q2 2026, selling an estimated $13M and leaving 82,526 shares worth $20.2M. The position accounts for 0.03% of the portfolio, ranked #503.

Man Group first reported a position in AXSM in Q2 2020 and has held it in 13 quarters since. The position peaked at $59.9M in Q1 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Man Group held 82,526 shares of Axsome Therapeutics worth $20.2M as of Q2 2026.
Man Group sold 59,745 Axsome Therapeutics shares in Q2 2026, an estimated $13M.
Axsome Therapeutics made up 0.03% of Man Group's portfolio in Q2 2026, its #503 holding.
Man Group first reported a position in Axsome Therapeutics in Q2 2020 and has held it in 13 quarters since.
Man Group's Axsome Therapeutics position peaked at $59.9M in Q1 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.